SCPH Tiesioginiai signalai | Didinkite pelną su Getagraph.com

PARDAVIMAS 107820 min ago

@ $5.41

Išleistas: 14 vas. 2024 @ 16:30

Grąža: -17.01%

Ankstesnis signalas: vas. 12 - 19:38

Ankstesnis signalas: Pirkimas

Grąža: -1.81 %

Live Chart Being Loaded With Signals

Commentary (26 bal. 2024 @ 23:00):

Stats
Šios dienos apimtis	119 733
Vidutinė apimtis	220 659
Rinkos kapitalizacija	161.88M
EPS	$0 ( 2024-03-13 )
Kita pelno data	( $-0.450 ) 2024-05-08
Last Dividend	$0 ( N/A )
Next Dividend	$0 ( N/A )
P/E	-3.16
ATR14	$0.00500 (0.11%)

Insider Trading

Date	Person	Action	Amount	type
2024-03-29	Tucker John H	Buy	56 025	Stock Option (right to buy)
2024-01-18	Nokes Rachael	Buy	62 755	Stock Option (right to buy)
2024-01-18	Nokes Rachael	Buy	41 840	Common Stock
2024-01-18	Tucker John H	Buy	113 560	Common Stock
2024-01-18	Tucker John H	Buy	170 340	Stock Option (right to buy)

INSIDER POWER
40.38
Last 97 transactions
Buy: 5 205 058 \| Sell: 2 188 570

Tūris Koreliacija

Ilgas: 0.12 (neutral)

Trumpas: -0.21 (neutral)

Signal:(44.818) Neutral

scPharmaceuticals Inc Koreliacija

10 Labiausiai teigiamai susiję koreliacijos
LWAC	0.907
SRAC	0.866
TBBK	0.852
NETE	0.829
HUBG	0.827
MMAC	0.816
SRAD	0.811
TWOU	0.809
MRTN	0.807
NXPI	0.804

10 Labiausiai neigiamai susiję koreliacijos
SVAC	-0.875
MTSL	-0.822
EGRX	-0.817
PAIC	-0.808

Ar žinojote?

Koreliacija yra statistinis rodiklis, aprašantis ryšį tarp dviejų kintamųjų. Jis svyruoja nuo -1 iki 1, kur -1 reiškia tobulo neigiamo ryšio koreliaciją (padidėjus vienam kintamajam, sumažėja kitas), 1 reiškia tobulo teigiamo ryšio koreliaciją (padidėjus vienam kintamajam, padidėja ir kitas), o 0 reiškia jokios koreliacijos (tarp kintamųjų nėra jokio ryšio).

Koreliacija gali būti naudojama analizuojant bet kurių dviejų kintamųjų ryšį, ne tik akcijų. Jis dažnai naudojamas finansų, ekonomikos, psichologijos ir kitose srityse.

scPharmaceuticals Inc Koreliacija - Valiuta/Žaliavos

-0.35
( neutral )

0.07
( neutral )

0.00
( neutral )

0.70
( moderate )

-0.67
( moderate negative )

scPharmaceuticals Inc Finansinės ataskaitos

Annual	2023
Pajamos:	$13.59M
Bruto pelnas:	$9.78M (71.96 %)
EPS:	$-1.420

FY	2023
Pajamos:	$13.59M
Bruto pelnas:	$9.78M (71.96 %)
EPS:	$-1.420

FY	2022
Pajamos:	$0
Bruto pelnas:	$-468 000 (0.00 %)
EPS:	$-1.320

FY	2021
Pajamos:	$0.00
Bruto pelnas:	$0.00 (0.00 %)
EPS:	$-1.020

Financial Reports:

No articles found.

scPharmaceuticals Inc

scPharmaceuticals Inc., a pharmaceutical company, engages in the development and commercialization of various pharmaceutical products. The company's lead product candidate is FUROSCIX that consists of formulation of furosemide, which is delivered through an on-body infusor for treatment of congestion in patients with heart failure. Its product pipeline also includes scCeftriaxone, an antibiotic to treat infections caused by gram-positive and gram-negative organisms; and scCarbapenem program, an antibiotic for treating infections caused by gram-negative organisms. The company has a development agreement with West Pharmaceutical Services, Inc. for development of single use SmartDose device. scPharmaceuticals Inc. was incorporated in 2013 and is headquartered in Burlington, Massachusetts.